WESTBOROUGH, Mass., July 10 /PRNewswire/ -- IBC Life Sciences is pleased to announce they have expanded the 12th Annual Drug Discovery & Development of Innovative Therapeutics world congress to include more case studies of projects in preclinical, phase 1 and phase 2. The coverage will be part of four therapeutic area (Cancer, CNS, Inflammatory Disease and Metabolic Disease) conference tracks.
The event will discuss a number of technologies and approaches used to accelerate the clinical development process including the use of biomarkers and imaging technologies for guiding clinical trials. Presentations will cover such topics as the challenges of worldwide clinical trial design and execution including such issues as establishing clinically relevant endpoints and patient enrolment.
Highlights from some of the clinically focused presentations attendees will hear in each therapeutic conference track are:
Cancer Track -- Late Stage Oncology Clinical Development: Challenges and Opportunities David Schenkein, Vice President, Clinical Oncology/Hematology, Genentech -- Case Studies in Oncology: Maximizing the Value of Biomarkers in Early Oncology Clinical Development Shujian Wu, Principal Scientist, Clinical Discovery, Bristol-Myers Squibb -- Biomarkers in Oncology Drug Development Case Study: The Use of Serum Her 2 ECD in the Development of an Oral Small Molecule Dual Tyrosine Kinase Inhibitor -- Lapatinib Steve H. Stein, Group Director, Medicine Development Center, Oncology, GlaxoSmithKline -- Circulating Tumor Cells in Phase 1 and 2 and their Use in Oncology Clinical Trial Design Gerald Doyle, Senior Director, Clinical Research, Immunicon Metabolic Diseases Track -- Trodusquemine: A Novel Aminosterol for the Treatment of Obesity and Related Metabolic Disorders Anthony Delconte, Vice President, Clinical Research and Development, Genaera Corporation -- Phase 2 Clinical Candidate: SLx-4090 Paul Sweetnam, Chief Scientific Officer, Surface Logix -- Panel Discussion: Hurdles and Failures in Late Stage Drug Development in the Metabolic Disease Area: Could they be Avoided? Lead Panellist: Frederik Lonnqvist, Vice President, Scientific and Clinical Business Development, Biovitrum Inflammatory Diseases Track -- MAP Kinase Inhibitors: Progress from Bench to Bedside Anthony M. Manning, Vice President and Global Head, Inflammation, Autoimmunity and Transplant Research, Roche Palo Alto LLC -- Case Study of the Development of an Orally Bioavailable Inhibitor of Syk Kinase in Inflammation Elliott Grossbard, Senior Vice President, Medical Development, Rigel, Inc CNS Track -- "Triple" Reuptake Inhibitors: From Bench to Bedside Phil Skolnick, President & CSO, DOV Pharmaceuticals -- Efficient Clinical Development of Antidepressants and Antianxiety Agents Tanya Ramey, Associate Director, Clinical Lead, Neuroscience, Clinical R&D, Pfizer, Inc.
The Drug Discovery & Development of Innovative Therapeutics (DDT) World Congress expects more than 3,000 pharmaceutical, biotechnology, government and academic researchers, executives and technology providers to participate. The event focuses on scientific innovations, new approaches and business strategies that are helping companies to accelerate movement of compounds into the clinic. In addition the four conference tracks this year's program includes three pre-conference summits, six focus area sessions and three post- conference workshops. DDT also provides one of the largest exhibitions of drug discovery and development related products, technologies and services in the world.
Complete world congress details can be found at http://www.drugdisc.com or to receive a press pass or arrange an interview with a speaker, email Dawn O'Connor at doconnor@ibcusa.com.
About IBC Life Sciences
IBC Life Sciences is the worldwide leader in scientific, technological and business conferences and courses for the life science industry. To develop its programs, IBC actively researches the advancements, technologies and trends impacting and driving the race for new drugs and therapies. No other organization can make claim to the breadth and quality that IBC Life Sciences delivers in each event giving the company recognition around the globe for quality, service and value. For more information, visit: http://www.IBCLifeSciences.com.
Contact: Dawn O'Connor IBC Life Sciences 508 - 614 - 1679 doconnor@ibcusa.com
IBC Life SciencesCONTACT: Dawn O'Connor of IBC Life Sciences, +1-508-614-1679,doconnor@ibcusa.com
